Article ; Online: Real-life data of immune recovery using bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV. Results at 48-96 weeks of RETROBIC Study.
The Journal of antimicrobial chemotherapy
2024 Volume 79, Issue 3, Page(s) 595–607
Abstract: Background: Switching strategy with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) has become a gold standard for people living with HIV (PLWH), achieving high efficacy and safety rates. However, data regarding immune status in long-term real- ...
Abstract | Background: Switching strategy with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) has become a gold standard for people living with HIV (PLWH), achieving high efficacy and safety rates. However, data regarding immune status in long-term real-life cohorts of pretreated patients are needed. Methods: We performed a multicentre, non-controlled, retrospective study in virologically suppressed PLWH switching to B/F/TAF. We evaluated CD4+, CD8+ and CD4+/CD8+ ratio, efficacy and safety at weeks 48 and 96. Results: The study comprised 1966 PLWH from 12 hospitals in Spain, of whom 80% were men, and the median age was 51.0 [42.0-57.0] years. The median time of HIV infection was 18.0 [10.0-27.0] years. No significant changes in CD4+, CD8+ T cells, or CD4+/CD8+ were observed after 96 weeks. Nevertheless, in women at weeks 48 and 96, we found a significant increase of CD4+ T cells and a significant decrease in CD8+ T cells. In patients ≥60 years at week 96, CD4 T cells significantly increased and CD8+ T cells significantly decreased at week 48. The on-treatment analysis revealed HIV-RNA <50 copies/mL in 95.6% (1700/1779) and 96.7% (1312/1356) of patients at weeks 48 and 96, respectively. The rates increased to 99.2% (1765/1779) and 99.7% (1352/1356) when considering HIV-RNA <200 copies/mL. No resistance mutations were detected in virologic failures. B/F/TAF discontinuations accounted for 10.2% (200). Simplification was the most common reason for discontinuation in 3.8% (74) of patients. Conclusion: In long-term virologically controlled PLWH, B/F/TAF achieved high efficacy rates and slightly improved immune status in women and individuals aged 60 and over after 48 and 96 of switching. |
---|---|
MeSH term(s) | Male ; Humans ; Female ; Middle Aged ; Aged ; HIV Infections/drug therapy ; Emtricitabine/therapeutic use ; Retrospective Studies ; Adenine/therapeutic use ; Treatment Outcome ; Drug Combinations ; Heterocyclic Compounds, 4 or More Rings/therapeutic use ; RNA ; Piperazines ; Tenofovir/analogs & derivatives ; Pyridones ; Alanine ; Amides ; Heterocyclic Compounds, 3-Ring |
Chemical Substances | tenofovir alafenamide (EL9943AG5J) ; bictegravir (8GB79LOJ07) ; Emtricitabine (G70B4ETF4S) ; Adenine (JAC85A2161) ; Drug Combinations ; Heterocyclic Compounds, 4 or More Rings ; RNA (63231-63-0) ; Piperazines ; Tenofovir (99YXE507IL) ; Pyridones ; Alanine (OF5P57N2ZX) ; Amides ; Heterocyclic Compounds, 3-Ring |
Language | English |
Publishing date | 2024-01-24 |
Publishing country | England |
Document type | Journal Article |
ZDB-ID | 191709-2 |
ISSN | 1460-2091 ; 0305-7453 |
ISSN (online) | 1460-2091 |
ISSN | 0305-7453 |
DOI | 10.1093/jac/dkae011 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 1197: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
|||
Zs.MO 124: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.